- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Carlsbad Today
By the People, for the People
Gain Therapeutics and Ionis Pharmaceuticals Compared
Analysts see more upside potential in Gain Therapeutics stock compared to Ionis Pharmaceuticals.
Published on Feb. 10, 2026
Got story updates? Submit your updates here. ›
Ionis Pharmaceuticals (NASDAQ:IONS) and Gain Therapeutics (NASDAQ:GANX) are both medical companies, but analysts believe Gain Therapeutics has more potential upside based on factors like institutional ownership, valuation, and profitability.
Why it matters
The comparison between these two biotech companies provides insight into their relative strengths and weaknesses as investment options in the medical sector.
The details
Ionis Pharmaceuticals has significantly higher institutional ownership at 93.9% compared to Gain Therapeutics at 12%. However, Gain Therapeutics has a higher percentage of insider ownership at 7.2% versus 2.7% for Ionis. Gain Therapeutics also has a lower beta of 0.06 versus 0.29 for Ionis, indicating it is less volatile. Analysts have a consensus target price of $8.67 for Gain Therapeutics, implying 384% potential upside, compared to $86.95 for Ionis or just 2.55% upside. In terms of valuation, Ionis trades at a lower price-to-earnings ratio. But Gain Therapeutics has higher earnings per share.
- The analysis was published on February 10, 2026.
The players
Ionis Pharmaceuticals
A biopharmaceutical company that discovers and develops RNA-targeted therapeutics, including treatments for spinal muscular atrophy, polyneuropathy, and familial chylomicronemia syndrome.
Gain Therapeutics
A biotechnology company that develops small molecule therapeutics to treat various diseases, including Parkinson's, Alzheimer's, and certain genetic disorders.
The takeaway
While Ionis Pharmaceuticals has stronger institutional backing, Gain Therapeutics appears to offer investors more potential upside based on its lower valuation, higher earnings, and greater analyst optimism around its future prospects.
